|
 About
Aradigm
Business Overview
Leadership
|
Aradigm is actively engaged in
fulfilling the promise of developing inhalation drug products that could
revolutionize the quality of life of patients with severe pulmonary
disease.
Since
1991, the company has attracted an outstanding team of scientists, engineers
and clinical experts who have been at the forefront of development of
advanced inhalation delivery products. This team for example, pioneered the
AERx® pulmonary delivery platform that was tested in thousands
of patients with drugs and biologics including insulin, fentanyl,
erythropoietin and nicotine. With the depth of experience and expertise in
inhalation delivery, Aradigm is uniquely positioned to develop a portfolio
of its own products to treat patients with severe respiratory diseases. The
current pipeline includes an inhaled antibiotic being developed for the
treatment of bronchiectasis*, cystic fibrosis and for biodefense, and
inhaled nicotine for smoking cessation.
* If you
would like to see a video explaining what bronchiectasis is, please, click
on this icon:
|
